Core Hypothesis

The nuclear RNA exosome complex, which degrades mis-spliced transcripts, has a finite processing capacity. In spliceosome-mutant cancers, accumulating aberrant isoforms—particularly intron-retained transcripts—eventually saturate this exosome capacity, triggering catastrophic RNA quality control failure, toxic protein aggregation, and irreversible fitness collapse.

Mechanistic Reasoning

Current models treat splicing-derived isoform burden as a linear correlate of dysfunction [1]. Yet cells tolerate substantial splicing noise until an undefined threshold. The exosome is the primary decay machinery for aberrant splice products, including intron-retained mRNAs and unstable intermediates [2]. Key elements:

1. Capacity limits: The nuclear exosome (via NEXT complex) has finite enzymatic sites. Each SF3B1-mutant cancer cell produces ~500–1,000 additional retained introns daily [3]. At high loads, competitive inhibition slows degradation of all aberrant transcripts.

2. Escape and toxicity: When exosome-saturated, retained introns escape to the cytoplasm. Their premature termination codons evade NMD but yield truncated proteins that misfold and aggregate, overwhelming the proteasome and triggering UPR/ER stress [4].

3. R-loop catastrophe: Undegraded intron-retained transcripts form stable R-loops at gene loci, causing replication stress and DNA damage that exceeds the already compromised repair capacity from hypomorphic BRCA1-Δ11q isoforms [1].

4. Threshold logic: Fitness collapse occurs when exosome occupancy on aberrant substrates exceeds 85–90% of total capacity—a quantifiable switch from adaptive tolerance to system failure.

Testable Predictions

• Dose-response: Titrate SF3B1 inhibition in isogenic cell lines; exosome saturation (measured by seCLIP occupancy) will correlate with sudden viability drop, not gradual decline.

• Exosome overexpression: Boosting EXOSC10 levels should raise the isoform burden threshold for cell death, delaying resistance to splicing modulators like H3B-8800 [1].

• Proteotoxic signature: At saturation, cells should show increased insoluble protein aggregates and chaperone sequestration, coinciding with loss of adaptive splicing factor expression.

• Clinical correlation: In MDS patients treated with splicing-targeted therapies, pre-treatment intron retention levels should predict response, with a sharp drop in efficacy above a calculable exosome burden index.

Why This Matters

This frames the "transcriptomic chaos" problem as a resource competition issue, not just signaling pathway activation. It also explains why single isoform switches (e.g., BCL2L1-L) confer resistance early, while systemic collapse requires cumulative load [1]. Therapeutically, combining exosome enhancers with spliceosome modulators could raise the saturation threshold and prevent escape.

[1] PMC12709091: spliceosome mutations drive oncogenesis via aberrant isoforms activating NF-κB/AKT and conferring therapy resistance. [2] PubMed 41448555: SF3B1 mutations reshape splicing via abnormal SUGP1/DHX15 interactions. [3] PMC12190615: antisense oligonucleotides correct specific splicing events. [4] Fred Hutch spotlight: aberrant splicing creates immunogenic neoantigens.